HONG KONG: Xenitra Limited said Wednesday it has acquired Hong Kong Fukang Trading Co., Limited, a move that fully activates its over-the-counter medicine business in Hong Kong and mainland China.
The ASX-listed company, which specializes in fast-moving consumer goods, nutraceuticals and OTC medicines, paid $469,243 for 100% of Fukang’s shares and related assets. Those include a Hong Kong pharmaceutical wholesale license, a JD.com store deposit, a trademark registration, warehouse logistics deposits and existing inventory.
Xenitra received authorization for its Hong Kong pharmaceutical wholesale license and cross-border OTC medicine business on Dec. 18, 2025.
The acquisition allows Xenitra to take over Fukang’s operations and expand OTC product offerings to the China market through the Hong Kong license and Fukang’s existing online storefronts.
“This is a meaningful step forward in this critical business unit,” said Anthony Noble, chairman of Xenitra. “Having this Hong Kong pharmaceutical license in place will allow the company to bring more new products into the China market seamlessly.”
The company has generated more than $70 million in sales since 2024 through B2B wholesale, retail distribution and ecommerce platforms across Asia.
This story has been corrected to show the acquisition date is April 15, 2026.